Mercantile Bank Corporation MBWM (Amortization) accretion on investments

(Amortization) accretion on investments at other companies

Oruka Therapeutics, Inc.ORKA

$446K-75.2%

Arbutus Biopharma CorporationABUS

$354K-50.7%

PegasystemsPEGA

$321K-79.0%

Capital City Bank GroupCCBG

-$792K+30.8%

Jackson FinancialJXN

$14M+75.0%

BancFirst CorporationBANF

$427K+676%

Revenue$67.6M+18.1%

Net income$22.7M+16.1%

EPS (diluted)$1.32+9.1%

Operating cash flow$28.3M+1,051%

CapEx$938.0K-39.0%

Free cash flow$27.4M+706%

Market cap$963.74M+36.5%

P/E10.5×+1.4×

P/S3.8×+0.7×

Net margin36.3%+2.7pp

FCF margin17%—

Return on equity8.6%—

Debt / equity0×—

Reported directly by Mercantile Bank Corporation in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.

The official record: Mercantile Bank Corporation’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Mercantile Bank Corporation's (amortization) accretion on investments?: Mercantile Bank Corporation (MBWM) reported (amortization) accretion on investments of $200K in Q1 2026.